Halozyme Therapeutics | HALO - 债务



金融业
股票价格
USD
资产
USD 2.67B
现金及等价物
USD 309.75M
销售成本
USD 108.75M
流动资产
USD 1B
流动负债
USD 363.21M
债务
USD 2.14B
EBIT
USD -61.77M
EBITDA
USD 219.57M
员工
350
EPS每股收益
USD 1.6
股本和储备
USD 219.64M
销售毛利
USD 297.47M
债务利息支出
USD 5.51M
贷款资金
USD 1.94B
市值
USD 8.56B
净收入
USD 150.05M
营业费用
USD 192.19M
营业利润
USD -61.77M
普通股股本
USD 118.52M
PE价格收益
11.35
税前利润
USD 180.33M
销售收入
USD 377M
销售和管理费用
USD 46.29M
股票
USD 155.47M
贸易债权人
USD 14.1M
应收帐款人
USD 457.99M


债务 更改 日
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amarin USD 0 0 2025-03
Amgen USD 54.6B 17M 2025-12
Baxter International USD 9.78B 68M 2025-12
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 1.29B 4.48M 2026-03
DBV Technologies USD 8.59M 295K 2025-09
Eli Lilly USD 42.5B 3.6M 2025-12
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Intrexon USD 0 13.82M 2024-06
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
MannKind USD 367.44M 247.53M 2025-12
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 0 0 2022-06
Pfizer USD 63.73B 231M 2026-03
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12